OR WAIT null SECS
Quotient Clinical’s addition of CDMO QS Pharma increases the company’s footprint in the US an adds high potency molecule capability.
Quotient Clinical announced on Feb. 14, 2017 the acquisition of QS Pharma, a contract development and manufacturing organization based near Philadelphia, from Charles River Laboratories International, Inc. The acquisition increases Quotient’s presence in the US and, will enable the company to replicate its Translational Pharmaceutics platform in America, according to a press statement. On Feb. 6, 2017, Quotient announced the acquisition of SeaView Research, a Florida-based clinical pharmacology business.
Founded in 2002, QS Pharma specializes in the formulation development and manufacturing of small-molecule drug products and supports customer programs through all stages of development and commercialization, including work with high potency molecules.
Quotient’s Translational Pharmaceutics platform integrates clinical testing with formulation development and real-time GMP manufacturing; more than 100 pharmaceutical and biotech companies have chosen Translational Pharmaceutics to accelerate the development of their products, the company reports.
Source: Quotient Clinical